Skinvisible, Inc., a topical drug delivery company, announced that it has been issued a second patent by the U.S. Patent and Trademark Office protecting the ‘Polymer Composition’ of the Company’s Invisicare polymer delivery system. When topically applied, Invisicare-formulated products hold active ingredients on the skin for up to four hours, thereby affording the active ingredients an extended timeframe to perform their intended functions.
Previously, a patent was issued to Skinvisible related to the ‘Method of Manufacturing’ Invisicare. A third patent application, related to ‘Methods of Use’ of Invisicare, is pending.
“The issuance of this second Invisicare patent protects the unique mechanism by which we can safely deliver formulated products using Invisicare to remain on the skin for extended periods of time, resulting in improved efficacy, longer duration of action, reduced irritation and lower dosage of active agent required. This patent thus represents another significant milestone for our company, one that continues to validate the novelty of our technology platform, Invisicare,” said Terry Howlett, president and chief executive officer of Skinvisible.